Clinical Trial Update: A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating multiple doses of ABT-089 in Alzheimer's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ABT-089

Snippet

Sponsor: Abbott | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED